ERC Consolidator Grant · 2022
In Silico Trials for Cartilage Regenerative Medicine Applications
Osteoarthritis (OA) is a highly prevalent disease, affecting 1 in 8 adults worldwide and is projected to increase by 60% in the next two decades. Due to the intricate interplay between multiple influencing factors such as mechanical loading and inflammation playing out over multiple length scales and tissue compartments, currently no disease-modifying drugs are available on the market. The INSTAnt CARMA project aims to harness the power of in silico trials to study OA onset and progression, as well as design endogenous (drugs) and exogenous (tissue engineered) therapies. A multiscale multifactorial in silico model of the knee joint will be established and validated with dedicated in vitro…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.